Date:11/4/2009

iluted share 3, Adjusted 3, Adjusted reconciliation 2009 (1) 2009 (1) ---- ---- ---- ---- Net income per diluted share on a GAAP basis $0.20 $0.11 $0.33 $0.23 - Cost of product sales 0.01 0.01 0.03 0.02 - Selling, general and administrative 0.04 0.02 0.11 0.09 - Research and development 0.01 0.01 0.05 0.04 Amortization of purchased intangibles 0.04 0.06 0.14 0.18 HeartWare transaction costs 0.02 - 0.21 - Impact of adoption of ASC 470-20 0.04 0.03 0.10 0.09 Unrealized gain on embedded option for convertible debt (0.09) - (0.09) - Income tax effect of non-GAAP adjustments (0.03) (0.06) (0.20) (0.16) Convertible debt dilution impact (2) (0.02) (0.01) (0.06) (0.04) ----- ----- ----- ----- Net income per diluted share on a non-GAAP basis $0.22 $0.17 $0.62 $0.45 ===== ===== ===== ===== Shares used in calculation of net Income per diluted share -- GAAP 58,006 56,703 57,859 55,689 Shares used in calculation of net Income per diluted share -- non-GAAP (2) 65,297 63,993 65,150 62,979 (1) Adjusted for the retrospective adoption of the accounting for convertible debt instruments that may be settled in cash upon conversion, including partial settlements, in accordance with ASC 470-20, Debt. (2) The company's total diluted share count on a non-GAAP basis for the three and nine months ended September 27
'/>"/>

SOURCE Thoratec Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA